Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) has announced that its CEO, Jean-Pierre Sommadossi, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 3:05 p.m. ET. A live webcast will be available on the company's website, with a replay offered for 90 days post-event. Atea focuses on developing oral therapies targeting life-threatening viral infections, including SARS-CoV-2, dengue virus, hepatitis C, and respiratory syncytial virus using a proprietary nucleotide prodrug platform.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AVIR declined 1.85%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET.
A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com
FAQ
When will Atea Pharmaceuticals participate in the Evercore ISI HealthCONx Conference?
Where can I watch the Atea Pharmaceuticals conference presentation?
What is Atea Pharmaceuticals focused on developing?
What is the ticker symbol for Atea Pharmaceuticals?
